The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Development Of A Slit Scanning Laser Ophthalmoscope As A Screening Tool In Glaucoma Diagnostics
Funder
National Health and Medical Research Council
Funding Amount
$195,830.00
Summary
Glaucoma is typified by progressive optic disc cupping and loss of fibres with consequent characteristic field defects. Direct imaging of the retina and quantitative assessment of such images greatly increases early diagnosis of this blinding disease. The proposed device, a laser line scanning ophthalmoscope, could support non-invasive imaging to obtain 3-D information in a simple and cost effective way. This could provide objective clinical parameters to support the decision making process.
Optimising Cognitive Screening In General Practice
Funder
National Health and Medical Research Council
Funding Amount
$300,550.00
Summary
Within the next 5 - 10 years it is likely that sophisticated combination pharmacotherapy for Alzheimer's disease will become available. Once intervention agents are available that affect the underlying disease process, it will be critical to accurately identify those patients who are in the earliest stages of cognitive decline. That is, failure to detect cognitive decline at an early stage will reduce the effectiveness of the intervention and be costly to the individual and society. At the same ....Within the next 5 - 10 years it is likely that sophisticated combination pharmacotherapy for Alzheimer's disease will become available. Once intervention agents are available that affect the underlying disease process, it will be critical to accurately identify those patients who are in the earliest stages of cognitive decline. That is, failure to detect cognitive decline at an early stage will reduce the effectiveness of the intervention and be costly to the individual and society. At the same time, the probability of falsely identifying an individual as having Alzheimer's disease needs to be reduced in order to avoid unnecessary testing, anxiety and distress, and expense. A sophisticated and highly flexible testing system to detect the earliest stages of memory impairment will be developed. The test will be administered over the web in a general practitioner's surgery enabling the collection of normative data on the population of greatest interest (elderly patients seeing their doctor). Voice recognition technology will be used in order to insure a user friendly environment. Stringent procedures to protect privacy will be employed. The test will be inexpensive and easy to take and will allow valid retesting so that it can be used as part of the routine health screening for the elderly. This will be a far more sensitive and specific indicator of the cognitive decline found in most neurodegenerative disorders such as Alzheimer's disease, and will enable general practitioners to be more confident in assessing their older patients. It will also reduce costly referrals by more accurately identifying those patients at risk. It is expected that the test will find acceptance amongst patients and their doctors and become a routine part of normal health screening for the elderly.Read moreRead less